-
Investigational new drug (IND) application of SC-102 was approved by CDE of NMPA
On August 8, 2024, Conjustar Biologics announced that the investigational new drug (IND) application for the company's second peptide-drug conjugate (PDC), SC-102 for Injection, for the treatment of advanced malignant solid tumors expressing EphA2, was approved by the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration.
넶12 2024-09-02 -
SC-101 has received Investigational New Drug (IND) approval from the U.S. Food and Drug
On May 31, 2024, Conjustar Biologics announced that its Nectin-4 targeting PDC drug SC-101 has received Investigational New Drug (IND) approval from the U.S. Food and Drug.
넶13 2024-05-31 -
First in China: SC-101, a Peptide Drug Conjugate (PDC), has been approved by the Chinese National Medical Products Administration.
First in China: the Phase Ⅰ FIH study of SC-101, a Nectin-4-targeting Peptide Drug Conjugate (PDC), has been approved by the Chinese National Medical Products Administration.
넶17 2024-01-03
